NPPA Directs Manufacturers To Submit Application For RP Fixation Of New Drugs Through Email Only

Mumbai : For further streamlining the procedure and processing of application in a time bound manner, the National Pharmaceutical Pricing Authority (NPPA) has directed manufacturers to submit application online in Form-I for retail price fixation of new drugs.

According to NPPA, with effect from April 1, 2021, no application in Form-I for retail price fixation of new drugs in physical form shall be accepted by NPPA. The application in Form-I for retail price fixation of new drugs shall be accepted through email id only at pricing-nppa@gov.in as mentioned in para 2 of office memorandum (OM) dated August 26, 2020.

NPPA had mooted a proposal last year in August 2020 to develop an online system for disposing and monitoring of applications filed under various provisions of DPCO-2013 towards ease of doing business.

According to a NPPA notice, “The manufacturers have been directed to refer to NPPA’s OM dated August 26, 2020 regarding development and implementation of ecosystem for timely disposal and monitoring of various applications filed with NPPA’ wherein it was observed that most of the new drug applications are received online which has helped in their faster processing in a time bound manner.”

Development and implementation of an ecosystem for timely disposal and monitoring of various applications filed under various provisions of DPCO, 2013 includes submission of Form-I for application for the pricing of new drugs.

NPPA has stipulated that the applicant companies need to submit the application with all requisite documents via email at pricing-nppa@gov.in.

It has also stipulated pharma companies to Form-l related to revised prices for scheduled formulations, Form-II related to quarterly return in respect of production/import and sale of NLEM Drugs and Form-V related to price list.

Pharma companies should submit these forms on Integrated Pharmaceutical Database Management System (IPDMS) within the prescribed timelines. Besides this, the application for the discontinuation of the production of scheduled formulation with all requisite documents should be sent via email at monitoringnppa@gov.in.

Applications for special price for packaging under paragraph 11(3) of DPCO 2013 can be submitted at pricing-nppa@gov.in.

As per NPPA recommendations, NPPA authority meeting would be preferably held every month. If due to certain circumstances the same could not be held in a particular month, the authority meeting would be held in subsequent months as per requirement. Meeting of the multidisciplinary committee of experts would be held prior to the authority meeting.

All Indian pharma manufacturer associations should upload the Uniform Code of Pharmaceutical Marketing Practices (UCPMP) on their website including the detailed procedure mentioned in paragraph 10 of the UCPMP regarding lodging of complaints.

A quarterly report mentioning details of the complaint received and the decision taken thereon should be submitted by the concerned association to NPPA within 30 days of the end of the quarter via email to monitoring-nppa@gov.in.

NPPA has also stipulated timelines for disposal of applications in different categories like in Form I which is related to new drug prices and the given timeline is within 60 days.

Form II is used for the revised prices of scheduled formulations and the stipulated timeline to file is within 15 days from the date of notification. Form III is applied for the purpose of quarterly returns in respect of production/import and sale of NLEM drugs and the set timeline for the manufacturer is within 15 days from the date of the end of quarter.

[pdf-embedder url=”https://medicarepharmabusiness.com/wp-content/uploads/2021/02/Form-I-OM-160221080633.pdf”]

Related Posts

Minister JP Nadda launches drug registry to standardise medicine-related information

Union minister of health and family welfare, Jagat Prakash Nadda launched the Drug Registry as a unified and standardised digital platform for drug-related information to address the issues including confusion…

Pharmexcil urges companies to adopt NCB voluntary code to prevent chemical diversion into illegal drug production

The Pharmaceuticals Export Promotion Council of India (Pharmexcil) has urged its member pharma companies to implement the Voluntary Code of Conduct (VCC) introduced by the Narcotics Control Bureau (NCB) to…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Minister JP Nadda launches drug registry to standardise medicine-related information

Minister JP Nadda launches drug registry to standardise medicine-related information

Pharmexcil urges companies to adopt NCB voluntary code to prevent chemical diversion into illegal drug production

Pharmexcil urges companies to adopt NCB voluntary code to prevent chemical diversion into illegal drug production

Govt review finds no common thread in post-delivery deaths

Gurgaon call centre busted for cheating people with fake weight-loss products, 3 women held

Gurgaon call centre busted for cheating people with fake weight-loss products, 3 women held

Madhya Pradesh toddler loses vision after doctor administers drops, probe underway

Madhya Pradesh toddler loses vision after doctor administers drops, probe underway

CDSCO Mandates SUGAM Portal for Post-Approval Changes (PAC) to Vaccine and Anti-Sera Import Licences

CDSCO Mandates SUGAM Portal for Post-Approval Changes (PAC) to Vaccine and Anti-Sera Import Licences